Irinotecan Accord

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Accord, is a Topoisomerase I inhibitor presented as an injection solution for intravenous use. It is used in the treatment of metastatic colorectal cancer and as adjuvant therapy for colon cancer in adult patients.

GNH USA supplies Irinotecan Accord as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Irinotecan is a topoisomerase I inhibitor used in colorectal cancer treatment pathways.

- Metastatic colorectal cancer: improves disease control and overall survival when combined with standard chemotherapy regimens. - Adjuvant therapy for colon cancer: reduces risk of recurrence after surgical resection in patients with high‑risk disease.

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often delayed and may be severe. - Neutropenia: reduced white blood cell count increasing infection risk. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Fatigue: generalized tiredness during treatment cycles. - Alopecia: hair thinning or loss. - Anorexia: decreased appetite.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care. - Severe colitis: life‑threatening intestinal inflammation. - Cholinergic syndrome: abdominal cramping, sweating, and bradycardia. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Thromboembolic events: rare clot formation in veins or arteries.

Before initiating therapy, clinicians should assess patient suitability and monitor for potential complications.

- Hematology monitoring: perform baseline and periodic complete blood counts. - Liver function assessment: evaluate hepatic enzymes and bilirubin before each cycle. - Dose adjustment: modify dosing in patients with moderate hepatic impairment. - Diarrhea management: implement prophylactic antidiarrheal measures and educate patients on early reporting. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; consult obstetric specialist. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Irinotecan can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce SN‑38 exposure and therapeutic effect. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): increase SN‑38 levels, raising toxicity risk. - Concurrent myelosuppressive agents: amplify risk of severe neutropenia and infection.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): enhanced bleeding risk due to mucosal injury. - Anticholinergic drugs: may exacerbate cholinergic syndrome symptoms. - Other anti‑diarrheal agents: adjust dosing to avoid excessive constipation or ileus.